Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Status:
Completed
Trial end date:
2015-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as
NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Radio Isotope Therapy of America
Collaborators:
CHI St. Luke's Health, Texas Excel Diagnostic Imaging Clinics RadioMedix Radiomedix, Inc.